Novartis Drug Kisqali Boosts Survival Rate Of Young Breast Cancer Patients Clinical trials featuring Novartis' Kisqali revealed the potential of the drug to extend the life of breast cancer patients. Results showed that when Kisqali was used along with hormone therapy, it could increase survival rates by 70.2 percent. by Ted Ranosa
'Spray and Pray' iMessage Scam Haunts iPhone Owners: How to Avoid Losing Your Hard-Earned Money From it
Hong Kong University Brings Albert Einstein to Life Using AI, Transforming Him into a Virtual Lecturer